Thoracic Radiotherapy Plus Durvalumab in Elderly and/or Frail NSCLC Stage III Patients Unfit for Chemotherapy - Employing Optimized (Hypofractionated) Radiotherapy to Foster Durvalumab Efficacy (IKF TRADE-HYPO)

This is a randomized, open-label, multicenter, phase II trial investigating the combination of thoracic radiotherapy plus Durvalumab in patients with locally advanced, unresectable NSCLC (stage III) that are unfit for chemotherapy (e.g. due to age and/or frailty). Toxizität, definiert durch das Auftreten von behandlungsbedingter Pneumonitis Grad ≥3 Objektives Ansprechen nach RECIST 1.1 Kriterien